What is HC Wainwright’s Estimate for VNDA Q1 Earnings?
Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 18th. HC ...
Vanda Pharmaceuticals (NASDAQ:VNDA) Given New $20.00 Price Target at HC Wainwright
Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC ...
Vanda (VNDA) Gets a Buy from H.C. Wainwright
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda (VNDA – Research Report) on February 14 and set a price target of ...
Vanda Pharmaceuticals price target raised to $20 from $18 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm ...
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts
In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4 ...
Vanda Pharmaceuticals' SWOT analysis: deep value play amid pipeline growth
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, has been navigating a complex landscape of ...
Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...